News
KOD
41.95
-2.69%
-1.16
Weekly Report: what happened at KOD last week (0406-0410)?
Weekly Report · 21h ago
Weekly Report: what happened at KOD last week (0330-0403)?
Weekly Report · 04/06 10:10
J.P. Morgan Reaffirms Their Buy Rating on Kodiak Sciences (KOD)
TipRanks · 04/04 12:21
Kodiak Sciences CFO John A. Borgeson disposes of common shares worth 1.2 million
Reuters · 04/03 00:27
Kodiak Sciences falls -8.7%
TipRanks · 04/02 16:07
U.S. RESEARCH ROUNDUP-Doordash, Phillips 66, United Therapeutics
Reuters · 04/02 07:21
KODIAK SCIENCES INC <KOD.O>: JP MORGAN RAISES TARGET PRICE TO $60 FROM $32
Reuters · 04/02 03:03
Morning News Wrap-Up 4/1/26: Today’s Biggest Stock Market Stories!
TipRanks · 04/01 16:49
Kodiak Sciences Stock (KOD) Rallies as Analysts Weigh In After Earnings
TipRanks · 04/01 16:27
Kodiak Sciences: When Clinical Progress Stops Excusing the Cash Burn Rate
Barchart · 04/01 16:02
PVH, Micron, Intel And Other Big Stocks Moving Higher On Wednesday
Benzinga · 04/01 15:48
Kodiak Sciences reports Q4 EPS ($1.05) vs (84c) last year
TipRanks · 04/01 15:15
Analysts Offer Insights on Healthcare Companies: DBV Technologies SA – American (DBVT) and Kodiak Sciences (KOD)
TipRanks · 04/01 14:20
Kodiak Sciences rises 10.7%
TipRanks · 04/01 14:07
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
TipRanks · 04/01 12:03
Reiterating Buy on Kodiak: GLOW2 Validates Zenkuda’s Durable Efficacy and Multi‑Indication Path to Accelerated BLA
TipRanks · 04/01 10:35
Kodiak Sciences Q4 net loss widens on higher R&D spending
Reuters · 03/31 20:55
Kodiak Sciences GAAP EPS of -$1.04 in-line
Seeking Alpha · 03/31 20:49
Kodiak Sciences FY25 net loss widens to $230 million; Q4 net loss $56.7 million
Reuters · 03/31 20:49
Kodiak Sciences Q4 EPS $(1.04) Misses $(1.00) Estimate
Benzinga · 03/31 20:47
More
Webull provides a variety of real-time KOD stock news. You can receive the latest news about Kodiak Sciences Inc. through multiple platforms. This information may help you make smarter investment decisions.
About KOD
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.